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Abstract
Eighty-one patients with oral squamous cell carcinoma (OSCC) received oral fluoropyrimidine UFT and radiotherapy
(RT) with or without an immunotherapeutic agent OK-432. Both overall survival and progression-free survival of pa-
tients who received RT + UFT + OK-432 were significantly longer than those of patients who received RT + UFT
(P= .0075 and P= .0175, respectively). Clinical response was also more favorable in RT + UFT + OK-432 group than
in RT + UFT group (P = .0066). Next, in vitro experiments were conducted to examine the effect of 5-fluorouracil
(5-FU) and X-ray irradiation in OK-432–induced immunity. Human peripheral blood mononuclear cells stimulated with
OK-432 produced helper T cell 1 (Th1)–type cytokines as well as interleukin-10 (IL-10) and transforming growth
factor–β (TGF-β), which are produced by Th2 and regulatory T cells (Tregs), respectively, and are inhibitory in anti-
tumor immunity. OK-432–induced IL-10 and TGF-β but not Th1 cytokines were significantly inhibited by 5-FU and/or
X-ray. 5-FU and X-ray also inhibited the expression of mRNAs for GATA-3 and Foxp3, which are transcription factors
for Th2 and Tregs, respectively, but not for T-bet, a transcription factor for Th1. In addition, 5-FU and X-ray decreased
the expression of mRNAs for suppressor of cytokine signaling 1 (SOCS1) and SOCS3. Antisense oligonucleotides for
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SOCS1 and SOCS3 markedly reduced OK-432–induced IL-10 and TGF-β. This is the first report clearly demonstrat-
ing that OK-432–based immunotherapy significantly enhanced the therapeutic effects of chemoradiotherapy in
patients with OSCC as well as elucidating the mechanism of the synergistic effect of immunochemoradiotherapy
in which 5-FU and radiation enhanced OK-432–induced Th1 response mediated by the inhibition of SOCS1 and
SOCS3 gene expression.
Neoplasia (2013) 15, 805–814
Introduction
Head and neck squamous cell carcinoma (HNSCC) represents the
fifth most frequently occurring cancer worldwide. Of the 1.6 million
diagnoses and 333,000 deaths each year worldwide due to HNSCC,
half are localized in the oral cavity [oral squamous cell carcinoma
(OSCC)] [1]. Despite recent advances in surgery, radiotherapy
(RT) and chemotherapy, the 5-year survival rate for patients with
this disease has remained at 50% for the past 30 years [2]. In ad-
dition, functional or aesthetic disturbance by surgery for OSCC
causes impairment of quality of life, and major surgery for patients
of advanced age might be impossible due to compromised hosts. One
approach to overcoming these problems is to develop a more effective
therapeutic method for OSCC that reduces the disturbances induced
by surgery.
UFT (Taiho Pharmaceutical Co, Tokyo, Japan) is an oral prepa-
ration combining tegafur, a prodrug of 5-fluorouracil (5-FU), and ura-
cil in a 1:4 ratio that is used widely in Asian countries for treatment
of solid tumors including HNSCC [3,4]. OK-432 (Chugai Pharma-
ceutical Co, Ltd, Tokyo, Japan), which is a penicillin-killed and lyoph-
ilized preparation of a low-virulence strain (Su) of Streptococcus pyogenes
(group A), is being successfully used as an immunotherapeutic agent
in many types of malignancies [5–7]. We have also reported that
OK-432–based immunotherapy exhibits a marked therapeutic ef-
fect in patients with OSCC [8,9]. It has been reported that OK-432
elicits antitumor effects by stimulating immunocompetent cells such
as macrophages, T cells, and natural killer cells [10,11] and that
OK-432 induces interleukin-12 (IL-12) and polarizes the T cell re-
sponse to a helper T cell 1 (Th1)–dominant state [12]. Recently, we
and other investigators demonstrated that OK-432 induces matura-
tion of dendritic cells (DCs), which are professional antigen-presenting
cells, and that OK-432–stimulated DCs can induce tumor antigen–
specific cytotoxic T lymphocytes in vitro as well as in vivo [13–16].
OK-432, which is generally called a “nonspecific immunotherapeutic
agent,” induces tumor antigen–specific immunity, and OK-432 is
therefore being watched with great interest. Furthermore, we have
clearly demonstrated the molecular events that an active component
contained in the OK-432 augments antitumor host responses through
Toll-like receptor (TLR)–related signals [15–19], which play essential
roles in innate immune responses to microbial pathogens based on their
ability to recognize pathogen-associated molecular patterns [20,21].
In the current study, we have investigated the efficacy of OK-432 in
the antitumor effect of the chemoradiotherapy (CRT) in patients with
OSCC and then examined in vitro the possibility that RT and UFT
might augment OK-432–induced antitumor immunity. We elucidate
the mechanism of the synergistic effect of the combination therapy
and propose the concept of a new cancer therapy, an immunochem-
oradiotherapy (ICRT), based on the results of the current study.
Materials and Methods
Patients and Treatment Protocol
This study was carried out in accordance with the standards of our
Institutional Committee for the Protection of Human Subjects. In-
formed written consent for study participation was obtained from all
patients, and the collection of samples was approved by the Institutional
Review Board. From 1994 to 2006, 81 patients (46 males and 35 fe-
males) with OSCC were treated with RT and UFT with or without
OK-432 at the Second Department of Oral and Maxillofacial Surgery,
Tokushima University Hospital. A summary of the patients’ profiles
appears in Table 1. The median patient age was 63.6 years (range,
36–85 years). On the basis of the Tumor-Node-Metastasis system for
the classification of malignant disease [22], there were 7 T1 cancers, 48
T2 cancers, 20 T3 cancers, 6 T4 cancers, 41 N0 cancers, 28 N1 can-
cers, 11 N2 cancers, and 1 N3 cancer. All cancers were M0. All of the
patients were histopathologically diagnosed as having SCC. Primary
sites of the tumors were the tongue (n = 42), upper gingiva (n = 12),
lower gingiva (n = 11), buccal mucosa (n = 6), floor of the mouth (n =
7), and hard palate (n = 3). All of the patients had primary diseases and
had not received any previous treatment. None of the patients was
severely immunodeficient as determined from clinical examinations.
All patients received UFT (300mg/day for 8 weeks) simultaneously in
combination with RT (a total irradiation dose of 50–60 Gy). Sixty-seven
of the 81 patients were administered OK-432 intradermally or peritu-
morally at a dose of 0.5 Klinische Einheit, i.e., 50 μg/week. When any
severe adverse events were not shown, the dose was increased up to
5 Klinische Einheit per week. Patients were monitored for general symp-
toms related to the therapy. Four weeks after completion of the therapy,
biopsy materials were taken from all of the treated patients for the assess-
ment of therapeutic effect. When any residual tumor cells were detected
in biopsymaterial(s), surgical resection of the tumor(s) was performed.Of
the patients who did not show complete response (CR), residual tumors
in seven patients could not be surgically resected because of the patients’
poor general condition, and one patient refused the operation. These
eight patients received further chemotherapy. The tumor responses to
the combination therapy were classified according to the Response Eval-
uation Criteria in Solid Tumors criteria. Adverse events were evaluated
by grading toxicity according to the National Cancer Institute Common
Terminology Criteria for Adverse Events guidelines, version 3.0.
Treatment In Vitro of Human Peripheral Blood
Mononuclear Cells
Healthy volunteer-derived peripheral blood mononuclear cells
(PBMCs; 1 × 107/ml) were isolated from heparinized venous blood by
Ficoll-Hypaque gradient density centrifugation. The PBMCs were
cultured in RPMI 1640 medium (Life Technologies, Inc, Gaithersburg,
806 Immunochemoradiotherapy for Oral SCC Tano et al. Neoplasia Vol. 15, No. 7, 2013
MD) containing 10%heat-inactivated FBS (Bio-Whittaker,Walkersville,
MD), treated once with a single dose of 2 Gy X-rays in vitro using an
X-ray irradiator (Hitachi Medico, Tokyo, Japan) and stimulated with
OK-432 (1 μg/ml) and 5-FU (0.5 μg/ml; Kyowa Hakko, Tokyo, Japan)
for 24 hours. In some experiments, PBMCs were irradiated (2 Gy)
or were treated with 5-FU (0.5 μg/ml) 0, 3, 6, or 12 hours before
OK-432 stimulation. To examine the role of suppressor of cytokine sig-
naling 1 (SOCS1) and SOCS3, we added sense and antisense oligonu-
cleotides (ODNs; 10 μM) of these molecules to the PBMC culture
treated with OK-432 using Effectene Transfection Reagent (Qiagen,
Inc, Valencia, CA). Sequences of sense and antisenseODNswere as given
follows. SOCS1 antisense, CACCTGGTTGTGTGCTACCATCC-
TAC; SOCS1 sense, GTAGGATGGTAGCACACAACCAGGTG;
SOCS3 antisense, CGGGAAACTTGCTGTGGGTGACCAT;
SOCS3 sense, ATGGTCACCCACAGCAAGTTTCCCG. Superna-
tants were analyzed for cytokines by ELISA, and expression of mRNAs
in the PBMCs was assayed by semiquantitative reverse transcription–
polymerase chain reaction (RT-PCR) as described below.
Cytokine Assay
Cytokines in the supernatants were analyzed by using ELISA kits. The
ELISA kits for human interferon-γ (IFN-γ), tumor necrosis factor-α
(TNF-α), transforming growth factor–β (TGF-β), IL-10, and IL-12 were
purchased from BioSource International, Inc (Camarillo, CA), and the
ELISA system for human IL-18was purchased fromMBL (Nagoya, Japan).
RNA Extraction and Semiquantitative RT-PCR
Expression of mRNAs for T-bet, GATA-3, Foxp3, SOCS1, SOCS3,
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a housekeep-
ing gene that was used as an internal control, was detected by semi-
quantitative RT-PCR. Total RNAs were extracted from the PBMCs
by a modified acid guanidinium thiocyanate–phenol–chloroform using
ISOGEN RNA extracting mixture (Nippon Gene, Toyama, Japan)
according to the manufacturer’s recommendations. One microgram
of total RNA was reverse-transcribed using Moloney murine leukemia
virus reverse transcriptase (Life Technologies, Inc) and random primers
(Life Technologies, Inc) in a volume of 20 μl at 42°C for 60 minutes.
Then, 2 μl of the reverse-transcribed mixture was subjected to PCR
[10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.01%
gelatin, 20 mM each dNTP (A,G,T,C), 0.5 U Taq polymerase (Takara
Bio, Otsu, Japan), and 0.2 5 pmol of each primer in a total volume
of 20 μl]. The primer sequences used for the current experiments
were given as follows: 5′-TCAACAACCACCTGTTGTGG-3′ as an
upstream primer and 5′-TCACCTCAACGATATGCAGC-3′ as a
downstream primer for T-bet, which yield a 405-bp fragment [23];
5′-AATGAACGGACAGAACCGG-3′ as an upstream primer and
5′-GGTCCAGATTCAGTGGTTGG-3′ as a downstream primer
forGATA-3, which yield a 651-bp fragment [23]; 5′-ATGCCTCCTC-
TTCCTTGA-3′ as an upstream primer and 5′-ATTGTGCCCTG-
CCCTTCTCA-3′ as a downstream primer for Foxp3, which yield
a 314-bp fragment [24]; 5′-CGCCTGCGGATTCTACTG-3′ as
an upstream primer and 5′-GCAGCTCGAAGAGGCAGT-3′ as a
downstream primer for SOCS1, which yield a 445-bp fragment [25];
5′-ATGGTCACCCACAGCAAGTTT-3′ as an upstream primer and
5′-TCACACTGGATGCGCAGGTTC-3′ as a downstream primer
for SOCS3, which yield a 293-bp fragment [25]; and 5′-GAAATCC-
CAGCACCATCTCCAGG-3′ as an upstream primer and 5′-GTGG-
TGGACCTCATGGCCCACCATG-3′ as a downstream primer for
GAPDH, which yield a 781-bp fragment [26]. We used 25, 27, or
30 PCR cycles to amplify the fragments, with each cycle consisting
of 94°C for 60 seconds, 55°C for 90 seconds, and 72°C for 150 sec-
onds, with an initial denaturation step of 94°C for 5 minutes and a final
Table 1. Summary of Characteristics of Patients with OSCC.
RT + UFT + OK-432 RT + UFT Total P value (RT + UFT + OK-432 vs RT + UFT)
Number of patients 67 14 81
Age 63.2 (range, 36–77) 65.1 (range, 38–85) 63.6 (range, 36–85) .891
Sex
M 38 8 46 1
F 29 6 35
Stage
I 5 0 5 .522
II 20 5 25
III 28 8 36
IV 14 1 15
T
1 7 0 7 .231
2 40 8 46
3 14 6 22
4 6 0 6
N
0 32 9 41 .715
1 24 4 28
2 10 1 11
3 1 0 1
M
0 67 14 81 1
1 0 0 0
Primary sites
Tongue 35 7 42 .768
Upper gingival 11 1 12
Lower gingival 8 3 11
Buccal mucosa 5 1 6
Floor of the mouth 6 1 7
Hard palate 2 1 3
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elongation step of 72°C for 5 minutes. PCR was carried out in a DNA
Thermal Cycler (Takara Bio). Amplified cDNA was electrophoresed
through 1.5% agarose gels containing 100 ng/ml ethidium bromide.
After electrophoresis, gels were illuminated with UV light, viewed,
and photographed (Polaroid type 667 film; Polaroid Corp, Cambridge,
MA). Densitometric analysis for the RT-PCR band patterns was done
usingNIH Image 1.59 software (National Institutes of Health, Bethesda,
MD). The relative density of each specific RT-PCR band was expressed
as a ratio to the density of GAPDH. The identification of each amplified
product was confirmed by automated DNA sequencing.
To determine the optimal condition for the semiquantitative RT-PCR
described above, we reverse-transcribed 0.1, 0.5, 1, and 5 μg of total
RNA, using identical PCR cycles (from 18 to 40). We decided to use
1 μg of total RNA as a template for RT and to use 25 cycles of PCR
amplification for GAPDH and SOCS3, 27 cycles for T-bet, GATA-3,
and Foxp3, and 30 cycles for SOCS1.
Induction and Stimulation of DCs
To generate DCs, healthy donor-derived PBMCs (9 × 106 per
3 ml/well) were placed into six-well plastic tissue culture plates (Becton
Dickinson Labware, Franklin Lakes, NJ) in RPMI 1640 medium
supplemented with 10% heat-inactivated FBS. After 2 hours of in-
cubation at 37°C, nonadherent cells were removed and adherent cells
were stimulated with granulocyte-macrophage colony-stimulating
factor (500 U/ml; PeproTech, London, United Kingdom) and IL-4
(250 U/ml; Genzyme, Boston, MA) to generate immature DCs
[16,19]. Flow cytometric analysis by using each specific antibody revealed
that the population of adherent cells remaining in the wells was composed
of >95% CD14+ monocytes and that the monocyte-derived cells treated
with granulocyte-macrophage colony-stimulating factor and IL-4 were
consistently >92% CD14− CD1a+ human DCs [16]. These DCs were
treated with X-ray, 5-FU, and OK-432 as described above. The super-
natants were collected for cytokine assay. The cells were provided for
allogeneic mixed lymphocyte reaction (MLR).
Allogeneic MLR
To evaluate the antigen-presenting ability of the DCs, we performed
an allogeneic MLR test. Different numbers of irradiated (30 Gy)
DCs were cultured with 2 × 105 allogeneic T cells (>95% CD3+)
purified from PBMCs by anti–CD3-coated microbeads and a mag-
netic cell sorting system (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany). After 5 days of cultivation, [3H]-thymidine (1 μCi/well) was
added to the cultures. Eighteen hours later, [3H]-thymidine uptake was
measured using a liquid scintillation counter. Cell-free supernatants
were harvested and stored at −80°C until the assay for IFN-γ.
Statistical Analysis
Kaplan-Meier curves and log-rank tests were used to assess differences
in survival time between the treatment groups. The relationship in clinical
responses was statistically evaluated by two-sided Fisher’s exact test. In
in vitro experiments, the data were evaluated using Student’s two-tailed
t test. Values of P < .05 were considered statistically significant.
Results
Antitumor Effect of OK-432 in OSCC Patients Receiving
RT and UFT
Although the current study is retrospective, and the number of pa-
tients in the RT + UFT treatment group was relatively low as compared
with that in the RT + UFT + OK-432 group, no statistically significant
relationship was observed between these two groups in background
of the patients including age (P = .891), sex (P = 1), stage (P = .522),
T (P = .231), N (P = .715), M (P = 1), and primary sites (P = .768;
Table 1).
Of 67 patients who received OK-432 in combination with RT and
UFT, 38 patients (56.7%) became histopathologically tumor-free
(CR) after the therapy without surgical resection, and 29 (44.3%)
showed partial response (PR). In contrast, of 14 patients who received
RT and UFT without OK-432, only 2 patients (14.3%) showed CR,
and 12 (85.7%) achieved PR after the therapy. A statistically significant
relationship in clinical response between patients who received RT +
UFT + OK-432 therapy and those who received RT + UFT alone
was observed (P = .0066; Table 2). These patients were observed
for more than 3 years after the therapies. Both overall survival and
progression-free survival of the RT + UFT + OK-432 group were
statistically significantly longer than in the RT + UFT group (P =
.0075 and P = .0175, respectively; Figure 1A). In the current cases,
when any residual tumor cells were detected in biopsy material(s),
surgical resection of the tumor(s) was performed. However, residual
tumors in eight patients were not surgically resected, as described
in the Patients and Treatment Protocol section. Thus, in Figure 1A,
right graph, “progression” contains tumor progression, relapse, and
appearance of new lesion.
Next, we elaborate on the clinical findings in three patients. In a
patient diagnosed with SCC of the lower gingiva with severe bone
destruction and invasion, the T4 tumor had completely disappeared
by the completion of therapy with RT + UFT +OK-432. Furthermore,
new bone formation was observed after the tumor had completely
regressed (Figure 1B). In a patient with SCC of the tongue, complete
remission of the large tongue tumor was observed after the therapy
(Figure 1C ). In a patient diagnosed with SCC of the maxilla with
metastasis to cervical lymph nodes, computed tomography demon-
strated the disappearance of the metastatic lymph nodes, and the relapse
of the tumor has not been observed in more than 6 years since the
completion of therapy (Figure 1D).
Effect of 5-FU and X-ray Irradiation in OK-432–Induced
Cytokine Production and mRNA Expression of
Transcription Factors in Human PBMCs: Regulation
of Th1/Th2/Regulatory T cell Balance
Wehave demonstrated that the antitumor effect of RT +UFT therapy
was augmented by OK-432. Recently, it has been suggested that certain
chemotherapeutic agents, including gemcitabine, 5-FU, a metronomic
dose of cyclophosphamide as well as irradiation, might be stimulatory
to host immunity or be inhibitory to suppressors of host responses such
as regulatory T cells (Tregs) and myeloid-derived suppressor cells and
Table 2. Comparison of Responses to RT + UFT Therapy with and without OK-432.
Clinical Responses Treatment
RT + UFT + OK-432 (%) RT + UFT (%) Total (%)
CR 38 (56.7) 2 (14.3) 40 (49.4)
PR 29 (44.3) 12 (85.7) 41 (50.6)
SD 0 0 0
PD 0 0 0
Total 67 (100) 14 (100) 81 (100)
The statistical relationship was detected by two-sided Fisher extract test (P = .0066).
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therefore enhance the effect of cancer immunotherapy [27–29]. Thus,
we next conducted in vitro experiments to examine whether 5-FU and
radiation may augment antitumor host responses induced by OK-432.
First, we investigated the effect of 5-FU and X-ray irradiation in
OK-432–induced cytokine production. CD4+ helper T cells that are
major cytokine-producing cells are divided into two subpopulations,
Th1 and Th2 cells. Th1 cells are induced by IL-12 or IL-18 and
produce IFN-γ, IL-2, and TNF-α. Th2 cells are induced by IL-4
and produce IL-4, IL-5, IL-6, IL-10, and IL-13 [30]. Th1-type cyto-
kines may be effective in eliminating cancer cells, and Th2-type cyto-
kines may inhibit a Th1-mediated antitumor effect [31]. Furthermore,
recent reports suggest that CD4+CD25+Foxp3+Tregs secrete TGF-β
and IL-10 and inhibit antitumor immunity [32]. It is important to
shift the cytokine balance to Th1 to obtain a therapeutic benefit in
cancer therapy.
Healthy donor-derived human PBMCs were treated with OK-432,
5-FU, and/or X-ray. OK-432 induced all of the cytokines tested.
5-FU slightly augmented OK-432–induced TNF-α production in
the PBMCs (P < .05). No significant effect of 5-FU in the induction
of IFN-γ, IL-12, or IL-18 was observed. X-ray irradiation also elicited
no significant change in OK-432–induced Th1-cytokine production.
Interesting results were obtained in the production of cytokines in-
hibitory to antitumor immunity. Both IL-10 and TGF-β were also
produced by OK-432–stimulated PBMCs. 5-FU slightly but signifi-
cantly inhibited OK-432–induced IL-10 production (P < .05) and
markedly inhibited TGF-β production (P < .01). Although IL-10
production was significantly decreased by X-ray irradiation (P < .01),
no significant inhibition by X-ray in OK-432–induced TGF-β was
observed (Figure 2A).
Next, PBMCs were treated by 5-FU or X-ray at 0, 3, 6, and 12 hours
before adding OK-432. Data were shown in Figure 2B. 5-FU slightly
augmented OK-432–induced IFN-γ production when 5-FU was
added at 3 hours before OK-432 stimulation (P < .05). 5-FU exhibited
no significant effect on IL-12 production. Likewise, we observed no
significant effect of X-ray irradiation on Th1-type cytokine production
induced by OK-432. Significant inhibition of IL-10 and TGF-β pro-
duction induced by OK-432 was observed when PBMCs were stim-
ulated by 5-FU or X-ray at almost all points before adding OK-432
(P < .01–.05; Figure 2B).
T-bet, GATA-3, and Foxp3 are important transcription factors for
Th1, Th2, and Tregs, respectively. We next examined the effect of
OK-432, 5-FU, and X-ray irradiation on gene expression of these
transcription factors and investigated the regulation of Th1/Th2/
Treg balance. OK-432 increased the expression of T-bet mRNA as
well as those of GATA-3 and Foxp3. 5-FU and X-ray elicited no sig-
nificant change in T-bet expression, while markedly decreased the
expression of GATA-3 and Foxp-3 mRNAs increased by OK-432
(Figure 2C ).
Figure 1. Antitumor effect of OK-432 in combination with RT and UFT. (A) Overall survival (left graph) and progression-free survival (right
graph) of patients who received RT + UFT + OK-432 therapy (solid lines) or RT + UFT therapy (dotted lines). (B) SCC of the lower gingiva
with severe bone destruction and invasion. The T4 tumor indicated by arrows in the upper left photograph had completely disappeared
after RT + UFT + OK-432 therapy, as indicated by arrows in the upper right photograph. The arrow in the lower left photograph indicates
bone destruction, and the arrow in the lower right photograph indicates new bone formation. (C) SCC of the tongue. Arrows in the
left photograph indicate the primary tumor. (D) SCC of the maxilla with metastasis to cervical lymph nodes. Pictures show computed
tomography of metastatic cervical lymph nodes. Arrows in the left and center pictures indicate metastatic lymph nodes.
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Although it has been reported that OK-432 is a potent Th1 in-
ducer, several reports have also suggested that OK-432 induces the
production of IL-10 and TGF-β mediated by a negative feedback
mechanism [12,33]. The findings obtained from the above experi-
ments strongly suggested that 5-FU and X-ray irradiation might
enhance the Th1-dominant state induced by OK-432 by inhibiting
differentiation of CD4+T cells to Th2 and Tregs, although aug-
mentation of the Th1 cytokine–inducing ability of OK-432 by these
agents was only marginal.
Role of SOCS1 and SOCS3 in the Th1-Dominant State
Induced by OK-432, 5-FU, and X-ray Irradiation
SOCSs act as negative feedback regulators following immunological
stimuli, and there is evidence to suggest that SOCS1 and SOCS3might
be Th1 inhibitors [34,35]. Therefore, we next examined the expres-
sion of mRNAs for SOCS1 and SOCS3 in PBMCs stimulated with
OK-432, 5-FU, and X-ray. OK-432 increased the expression of
mRNAs of SOCS1 and SOCS3. 5-FU and X-ray irradiation inhib-
ited the expression of both genes enhanced by OK-432 (Figure 3A).
To investigate the role of SOCS1 and SOCS3 in the Th1-dominant
state induced by OK-432, we assessed the effect of antisense ODNs
for SOCS1 and for SOCS3 in OK-432–induced cytokine production.
Antisense ODNs for SOCS1 and SOCS3 elicited no significant change
in the production of IFN-γ or IL-12 induced by OK-432, while these
antisense ODNs significantly inhibited OK-432–induced production
of IL-10 and TGF-β (P < .01–.05; Figure 3B). These results were
similar to those from the experiments using 5-FU and X-ray.
Effect of 5-FU and X-ray Irradiation on the Function of
DCs Activated by OK-432
We previously demonstrated that OK-432 induces maturation of
DCs and that OK-432–stimulated DCs can induce tumor antigen–
specific cytotoxic T lymphocytes in vitro as well as in vivo [15,16,19].
In the present study, we thus examined the effect of 5-FU and X-ray
irradiation on DC function activated by OK-432. Although IL-12 pro-
duction by OK-432–stimulated DCs was slightly increased by X-ray
irradiation (P < .05), production of TGF-β was significantly decreased
by treatment with 5-FU and by X-ray (P < .01–.05; Figure 4A). Other
Figure 2. Effect of 5-FU and X-ray irradiation on OK-432–induced cytokine production and mRNA expression of transcription factors
in human PBMCs: Regulation of Th1/Th2/Treg balance. (A) Healthy donor-derived PBMCs were treated with OK-432 (1 μg/ml), 5-FU
(0.5 μg/ml), and/or X-ray (2 Gy) at 24 hours before collecting supernatants, and then the supernatants were analyzed for cytokines.
(B and C) The PBMCs were irradiated (2 Gy) or were treated with 5-FU (0.5 μg/ml) at 0, 3, 6, or 12 hours before OK-432 stimulation. After
OK-432 was added, the supernatants were analyzed for cytokines (B), and mRNAs isolated from the PBMCs were assayed for expression
of T-bet, GATA-3, and Foxp3 (C). *P < .01, #P < .05 as compared with respective controls treated with OK-432 alone.
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cytokines tested were not detected in supernatants derived from any of
the DC cultures (data not shown). To evaluate the antigen-presenting
ability of DCs, we performed an allogeneic MLR test in which DCs
treated with each stimulus were co-cultured with allogeneic T cells. In
comparison with DCs treated with OK-432 alone, OK-432–treated
DCs co-stimulated with 5-FU and/or X-ray showed a higher ability
to stimulate the proliferation of allogeneic T cells (data not shown).
The cell-free supernatants derived from the allogeneic MLR culture
were analyzed for IFN-γ. Data from the allogeneic MRL culture at a
DC/T ratio of 1:20 are shown in Figure 4B. Similar to the data ob-
tained from the proliferation assay, allogeneic T cells co-cultured with
DCs stimulated by OK-432 in combination with 5-FU and/or X-ray
secreted IFN-γ more than did those co-cultured with DCs treated
with OK-432 alone (P < .01–.05). DCs stimulated with any stimuli
did not produce IFN-γ.
Discussion
Several investigators including our group demonstrated that irradiation
and treatment with certain chemotherapeutic agents might augment
host immunity and reported the data suggesting the possibility that
immunotherapy in combination with RT and/or chemotherapy may
be effective in patients with malignancies [27–29,36,37], while there
are only a few reports that clearly showed that ICRT practically
prolonged the survival of patients with malignant diseases including
OSCC, as compared with CRT alone. The results obtained from the
current study clearly indicated that the combination therapy by using
RT, UFT, and OK-432 had a striking anticancer effect far better than
that with RT + UFT alone and strongly suggested that the ICRTmight
be efficient in the treatment of OSCC patients. Although the current
study is retrospective, and the number of patients in the RT + UFT
treatment group was relatively low as compared with that in the RT +
UFT + OK-432 group, our study results might be beneficial for
establishing more effective cancer therapy, as a statistically significant
difference was still obtained.
Although these findings were obtained using the nonspecific immuno-
therapeutic agent OK-432, recently called an “old biological response
modifier (BRM),” we expect CRT to enhance the antigen-specific
immunity induced by specific immunotherapy such as cancer vaccines,
Figure 3. Role of SOCS1 and SOCS3 in the Th1-dominant state induced by OK-432, 5-FU, and X-ray irradiation. (A) Effect of 5-FU and
X-ray in OK-432–induced mRNAs for SOCS1 and SOCS3. PBMCs were irradiated (2 Gy) or were treated with 5-FU (0.5 μg/ml) at 0, 3, 6, or
12 hours before OK-432 stimulation (1 μg/ml). After OK-432 was added, we assayed the expression of mRNAs for SOCS1 and SOCS3
in the PBMCs. (B) Effect of antisense ODNs of SOCS1 and SOCS3 mRNAs in OK-432–induced cytokines. Sense and antisense ODNs
(10 μM) of these molecules were added with Effectene Transfection Reagent into the PBMC culture treated with OK-432. After 24 hours,
the supernatants were analyzed for cytokines. *P < 0.01, #P < 0.05 as compared with respective controls treated with OK-432 alone.
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because we have already reported that one of the principal effects of
OK-432 is enhancement of antigen-specific immunity through matura-
tion of DCs mediated by TLR4 signaling [9,15,16]. We have already
reported that the cancer vaccine based on OK-432–treated DCs in
combination with gemcitabine and/or S-1 might prolong the survival
of the patients with advanced pancreatic carcinoma refractory to standard
treatment in a retrospective clinical study [38], and further, we have
started a prospective clinical trial of a DC-based cancer vaccine in com-
bination with chemotherapy in several types of malignancies. We expect
the therapy to demonstrate an anticancer ability.
CRT is used as a first-line treatment for many inoperable cases
as well as for operable cases as an adjuvant or a neoadjuvant therapy,
and the present findings strongly suggest that ICRTmay be available as
a first-line therapy for many types of malignancies. Previously, in most
cases, cancer patients have received immunotherapies after the failure
of standard treatments, since it was then believed that the combination
of standard CRT and immunotherapy was not favorable because of
inhibitory effects of host immunity by the standard CRT. However,
many investigators and clinicians now understand that taking the im-
munotherapy to patients at an earlier stage is more effective for cancer
treatment. We expect the antitumor effect of ICRT as a first-line ther-
apy. In addition, recently a lot of molecular targeting agents such as
tyrosine-kinase inhibitors, which have little inhibitory effects as well
as having stimulating ability in host immunity [39], are being devel-
oped to be used clinically. There is also great interest in the combina-
tion therapy using tyrosine-kinase inhibitors as well as metronomic
chemotherapy and cancer vaccines. We are now also planning a clinical
trial using this combination.
Th1 shift in cytokine balance is an important event in this therapy
combined with an immune adjuvant OK-432. We have reported that
the patients whose serum IFN-γ levels were increased after OK-432
administration showed favorable clinical outcome [9,40]. In the pres-
ent findings, although augmentation of IFN-γ secretion by 5-FU and
irradiation was detected only little in the experiments using PBMCs
(Figure 2B), allogeneic MLR using DCs treated with OK-432, 5-FU,
and/or X-ray demonstrated IFN-γ production significantly more than
that using DCs stimulated only by OK-432 (Figure 4B). DCs may play
significant roles in the oral cancer patients who received OK-432.
The findings from the present in vitro experiments clearly demon-
strated that X-ray irradiation and 5-FU augmented Th1 responses
induced by OK-432 through regulating IL-10 and TGF-β mediated
by the inhibition of negative regulators SOCS1 and SOCS3. Although
OK-432 induces IL-12 and IFN-γ as potent Th1 inducers, IL-10 is also
induced through a negative feedback loop at 12 to 24 hours after
OK-432 stimulation [[12] and authors’ personal data]. It was also
reported that TGF-β is induced by OK-432 [33]. In the present in vitro
experiments, expression of mRNAs for SOCS1 and SOCS-3 was in-
creased at least within 24 hours after adding OK-432 into the PBMC
Figure 4. Effect of 5-FU and X-ray irradiation on the function of DCs activated by OK-432. (A) Production of IL-12 and TGF-β by DCs treated
with OK-432, 5-FU, and X-ray. Monocyte-derived DCs were treated with OK-432 (1 μg/ml), 5-FU (0.5 μg/ml), and/or X-ray (2 Gy) at 24 hours
before collecting supernatants, and then the supernatants were analyzed for IL-12 and TGF-β. (B) IFN-γ production by allogeneic T cells
stimulated by DCs treated with OK-432, 5-FU, and X-ray. Different numbers of irradiated (30 Gy) DCs were cultured with 2 × 105 allogeneic
T cells (>95% CD3+) purified from PBMCs by anti–CD3-coated microbeads and a magnetic cell sorting system. After 5 days of cultivation,
cell-free supernatants were analyzed for IFN-γ. Data from the experiments performed at a DC/T ratio of 1:20 are shown. *P < 0.01, #P <
0.05 as compared with respective controls treated with OK-432 alone.
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culture. It was reported that SOCS3 inhibits Th1 cells by suppressing
IL-12–mediated signal transducer and activator of transcription 4 and
that SOCS3 regulates the onset and maintenance of Th2-mediated aller-
gic response [34,35]. Furthermore, SOCS1 completely inhibits TLR4
signaling, and SOCS3 blocks the TLR4-mediated IL-6 signal but not
the IL-10 signal [34,41], while OK-432 augments antitumor immunity
through TLR4 signaling, as reported by our group [9,15,16,19]. Thus,
it appears that 5-FU and X-ray irradiation might interrupt the negative
feedback loop by inhibiting expression of SOCS1 and SOCS3 genes and
then augmenting the OK-432–induced Th1 response in patients with
OSCC. In the future, molecular targeting therapy against SOCSs in
combination with immunotherapy may be useful in the treatment of pa-
tients with malignancies. The development of new molecular targeting
is ongoing in our laboratory by using small interfering RNA technology.
On the basis of the findings of the current study, we have proposed the
concept of a new cancer therapy called ICRT as well as new therapeutic
targets that are negative regulators for antitumor host immunity.
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